Lupin and Boehringer enter $720m anti-cancer drug partnership

05-09-2019

Sarah Morgan

Lupin and Boehringer enter $720m anti-cancer drug partnership

nitpicker / Shutterstock.com

Indian drugmaker Lupin and German pharma company Boehringer Ingelheim have formed an alliance to develop a therapy for patients with difficult-to-treat cancers.


Lupin, Boehringer Ingelheim, cancer, oncology, licensing agreement, AbbVie, commercialisation

LSIPR